Company Profile

Changzhou Sunlight Pharmaceutical Co.,Ltd.
Year Established : 1990
Total Assets(USD) : choose not to disclose
Total Number of Staff : 300 to 349
Main Competitive Advantages : International Approvals/Standards,Experienced R&D Staff,Production capacity,Large Product Line,Contract Manufacturing
Other Competitive Advantages : 1. High Pressure Catalytic Hydrogenation 2. Cryogenic Reaction (≤-78℃) 3. High Pressure Hydrogenolysis Reaction 4. Heck, Suzuki, Negishi, Sonogashira 5. Aromatic Heterocyclic Synthesis 6. Rearrangement Reaction 7. Chiral Resolution 8. Grignard Reaction
Patents and Copyrights :
  • Contact Person :
  • Fax:
Founded in 1990, our company is located in Benniu Town, Changzhou City, Jiangsu Province, China. It is close to the Beijing-Shanghai High-Speed Railway, Shanghai-Nanjing Expressway, and Changzhou Airport via convenient transportation. Sunlight Pharm owns several manufacturing plants: Changzhou plants (mainly manufacture Formulation proudct; API and pharmaceutical intermeidates); Yancheng plant (mainly manufactures pharmaceutical intermediates and specialty chemicals) and Dalian plant built in 2020 (mainly manufacture pharmaceutical intermediates and high performance polymer monomers) and Shandong plant newly built in 2023 (mainly manufacture pharmaceutical intermediates, high performance polymer monomers and specialty chemicals). API has already passed EDQM, US FDA, Japan PMDA and China NMPA audit. Sunlight has got new version Chinese GMP certificate and EU GMP certificate and COS certificate. The APIs conform to BP, USP, and EP11.1. Moreover, Sunlight got ISO9001:2015 and ISO14004:2015 certificate for chemical products. Sunlight provides not only API and Pharmaceutical intermediates production but also custom synthesis. Our technology advantages are High Pressure Catalytic Hydrogenation, Cryogenic Reaction (≤-78℃), Grignard Reaction, and Oxidation Reaction, etc. We have our own R&D team.
Certificates/Standards
PharmaSources Customer Service